{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:34:19Z","timestamp":1779302059397,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ejim.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T13:01:54Z","timestamp":1422536514000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Risk identification and possible countermeasures for muscle adverse effects during statin therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Paolo","family":"Magni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Macchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Morlotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-7061","authenticated-orcid":false,"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2015.01.002_bb0005","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.2013.281348","article-title":"Statin therapy for primary prevention of cardiovascular disease","volume":"310","author":"Taylor","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2015.01.002_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2015.01.002_bb0015","unstructured":"Information USFaDAFCH. FDA Expands Adiveon Statin Risks. 2014;January."},{"key":"10.1016\/j.ejim.2015.01.002_bb0020","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejim.2014.03.003","article-title":"Statin therapy and related risk of new-onset type 2 diabetes mellitus","volume":"25","author":"Ruscica","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0030","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0035","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"An assessment by the Statin Cognitive Safety Task Force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","article-title":"Drug-related myopathies of which the clinician should be aware","volume":"12","author":"Valiyil","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ejim.2015.01.002_bb0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1586\/14779072.6.7.955","article-title":"Clinical characterization and molecular mechanisms of statin myopathy","volume":"6","author":"Toth","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0055","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1586\/14779072.6.7.971","article-title":"Statin myopathy as a metabolic muscle disease","volume":"6","author":"Phillips","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2015.01.002_bb0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjp.0706917","article-title":"Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study","volume":"149","author":"Pierno","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0070","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2015.01.002_bb0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/jama.1988.03410020105038","article-title":"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients","volume":"260","author":"Corpier","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2015.01.002_bb0080","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2015.01.002_bb0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.beem.2014.01.006","article-title":"Overcoming toxicity and side-effects of lipid-lowering therapies","volume":"28","author":"Wilkinson","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2015.01.002_bb0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.phrs.2014.04.012","article-title":"Statins and skeletal muscles toxicity: from clinical trials to everyday practice","volume":"88","author":"Norata","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2015.01.002_bb0095","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4103\/2230-8210.113754","article-title":"Safety of statins","volume":"17","author":"Maji","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ejim.2015.01.002_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0105","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0110","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2015.01.002_bb0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0120","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0125","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0130","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0135","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2015.01.002_bb0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.archger.2008.12.012","article-title":"Statin therapy in the elderly: a review","volume":"50","author":"Szadkowska","year":"2010","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.ejim.2015.01.002_bb0145","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2015.01.002_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2015.01.002_bb0155","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.atherosclerosis.2014.10.108","article-title":"Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients >\/=80years of age: observations from the CREDO-Kyoto Registry Cohort-2","volume":"237","author":"Natsuaki","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2015.01.002_bb0160","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0165","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2014.10924","article-title":"Evaluation and treatment of older patients with hypercholesterolemia: a clinical review","volume":"312","author":"Strandberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2015.01.002_bb0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Expert Dyslipidemia","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin-associated myopathy","volume":"159","author":"Rallidis","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0180","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician's guide to statin drug\u2013drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0185","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0828-282X(06)70310-5","article-title":"Canadian Cardiovascular Society position statement\u2014recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease","volume":"22","author":"McPherson","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002040","article-title":"Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information","volume":"3","author":"Chang","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2015.01.002_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ejim.2015.01.002_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853890.2011.582135","article-title":"Clinical response to statins: mechanism(s) of variable activity and adverse effects","volume":"44","author":"Sirtori","year":"2012","journal-title":"Ann Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0205","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/gim.2014.41","article-title":"Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review","volume":"16","author":"Canestaro","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/157016112799305021","article-title":"Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin","volume":"10","author":"Catapano","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0215","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pds.3199","article-title":"Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network","volume":"21","author":"Rowan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejim.2015.01.002_bb0220","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clpt.2006.02.013","article-title":"On the mechanisms of statin-induced myopathy","volume":"79","author":"Laaksonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0225","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0230","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2015.01.002_bb0235","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","article-title":"Pitavastatin\u2014pharmacological profile from early phase studies","volume":"11","author":"Catapano","year":"2010","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.ejim.2015.01.002_bb0245","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2007.01.067","article-title":"Safety of aggressive lipid management","volume":"49","author":"Davidson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0250","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2015.01.002_bb0255","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2015.01.002_bb0265","author":"FDA"},{"key":"10.1016\/j.ejim.2015.01.002_bb0270","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2015.01.002_bb0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80mg versus 10mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0280","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cmet.2013.11.012","article-title":"Does reduced creatine synthesis protect against statin myopathy?","volume":"18","author":"Ballard","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejim.2015.01.002_bb0285","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11883-013-0347-3","article-title":"The effect of statins on skeletal muscle function: the STOMP trial","volume":"15","author":"Farmer","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ejim.2015.01.002_bb0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.atherosclerosis.2013.07.044","article-title":"STOMPing forward: statins, muscle complaints and CK","volume":"230","author":"Laaksonen","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2015.01.002_bb0295","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1567-5688(11)70888-1","article-title":"Pitavastatin: clinical effects from the LIVES Study","volume":"12","author":"Teramoto","year":"2011","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.ejim.2015.01.002_bb0300","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.clinthera.2014.06.009","article-title":"Comparison of the lipid-lowering effects of pitavastatin 4mg versus pravastatin 40mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial","volume":"36","author":"Sponseller","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0305","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0310","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0315","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2009-2689","article-title":"Approach to the patient who is intolerant of statin therapy","volume":"95","author":"Eckel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2015.01.002_bb0320","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/MOL.0b013e328348a513","article-title":"Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches","volume":"22","author":"Catapano","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity","volume":"23","author":"Sathasivam","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0330","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2014.02.023","article-title":"Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review","volume":"36","author":"Mergenhagen","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2015.01.002_bb0335","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/hrt.2010.199034","article-title":"Individualising the risks of statins in men and women in England and Wales: population-based cohort study","volume":"96","author":"Hippisley-Cox","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2015.01.002_bb0340","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0345","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0350","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ejim.2015.01.002_bb0355","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2015.01.002_bb0360","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejim.2015.01.002_bb0365","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejim.2015.01.002_bb0370","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11883-014-0475-4","article-title":"Non-traditional dosing of statins in statin-intolerant patients\u2014is it worth a try?","volume":"17","author":"Cornier","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ejim.2015.01.002_bb0375","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S11244","article-title":"Treating statin-intolerant patients","volume":"4","author":"Arca","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ejim.2015.01.002_bb0380","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/HCO.0b013e3283605fa2","article-title":"New therapies to reduce low-density lipoprotein cholesterol","volume":"28","author":"Wierzbicki","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/met.2012.0103","article-title":"Colesevelam plus rosuvastatin 5mg\/day versus rosuvastatin 10mg\/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose","volume":"11","author":"Florentin","year":"2013","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.ejim.2015.01.002_bb0390","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0395","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacl.2011.11.002","article-title":"The high-dose rosuvastatin once weekly study (the HD-ROWS)","volume":"6","author":"Backes","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2015.01.002_bb0400","series-title":"Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus","first-page":"8","author":"Ruscica","year":"2014"},{"key":"10.1016\/j.ejim.2015.01.002_bb0405","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","article-title":"Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial","volume":"150","author":"Becker","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2015.01.002_bb0410","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","article-title":"Tolerability of red yeast rice (2,400mg twice daily) versus pravastatin (20mg twice daily) in patients with previous statin intolerance","volume":"105","author":"Halbert","year":"2010","journal-title":"Am J Cardiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T23:03:46Z","timestamp":1651100626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620515000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0953620515000035"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2015.01.002","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk identification and possible countermeasures for muscle adverse effects during statin therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}